Stifel initiated coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy rating and a $25 price target. The stock trades at $6.37, offering significant upside.
The firm highlighted Eupraxia's Diffusphere platform, which delivers therapies over extended durations. The company targets underserved conditions.
Eupraxia is validating its platform with fluticasone propionate for gastrointestinal conditions like eosinophilic esophagitis.
Stifel sees potential for a pipeline-in-a-product strategy. The company has a strong balance sheet with a current ratio of 19.3.
Recent news includes updates from the RESOLVE trial and the appointment of Dr. Jeymi Tambiah as CMO.
